| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Severe Acute Respiratory Syndrome | 48 | 2020 | 12361 | 0.96 | Why? |
| Coronaviridae | 8 | 2014 | 923 | 0.79 | Why? |
| SARS Virus | 44 | 2020 | 13021 | 0.72 | Why? |
| Microbial Viability | 1 | 2020 | 406 | 0.63 | Why? |
| Hong Kong | 33 | 2021 | 3361 | 0.57 | Why? |
| Virulence | 3 | 2021 | 2172 | 0.56 | Why? |
| Nucleocapsid Proteins | 19 | 2020 | 3120 | 0.49 | Why? |
| Chiroptera | 14 | 2020 | 3530 | 0.46 | Why? |
| Molecular Diagnostic Techniques | 9 | 2020 | 4239 | 0.46 | Why? |
| Fluorescent Antibody Technique, Indirect | 3 | 2013 | 393 | 0.44 | Why? |
| Viral Envelope Proteins | 12 | 2020 | 3539 | 0.43 | Why? |
| Virus Inactivation | 1 | 2020 | 1139 | 0.42 | Why? |
| Respiratory Tract Infections | 12 | 2020 | 6817 | 0.37 | Why? |
| Antibodies, Viral | 30 | 2021 | 51949 | 0.36 | Why? |
| Genome, Viral | 23 | 2021 | 13157 | 0.35 | Why? |
| Influenza, Human | 12 | 2019 | 10779 | 0.34 | Why? |
| Sequence Analysis, DNA | 16 | 2019 | 2830 | 0.34 | Why? |
| Membrane Glycoproteins | 10 | 2013 | 2273 | 0.34 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 24 | 2021 | 13720 | 0.33 | Why? |
| Real-Time Polymerase Chain Reaction | 10 | 2021 | 11367 | 0.33 | Why? |
| Adenoviruses, Human | 2 | 2018 | 195 | 0.32 | Why? |
| Recombination, Genetic | 6 | 2017 | 1265 | 0.32 | Why? |
| Coronavirus | 27 | 2020 | 18339 | 0.31 | Why? |
| Molecular Sequence Data | 20 | 2014 | 3198 | 0.31 | Why? |
| Camelus | 5 | 2019 | 1425 | 0.31 | Why? |
| Roseolovirus Infections | 2 | 2017 | 131 | 0.30 | Why? |
| Coronavirus OC43, Human | 4 | 2011 | 1157 | 0.29 | Why? |
| Phylogeny | 28 | 2021 | 13341 | 0.29 | Why? |
| Viral Load | 21 | 2020 | 15850 | 0.28 | Why? |
| Cross Reactions | 4 | 2017 | 4374 | 0.28 | Why? |
| Herpesvirus 6, Human | 2 | 2017 | 162 | 0.28 | Why? |
| Zika Virus | 4 | 2018 | 1924 | 0.28 | Why? |
| Coronavirus 229E, Human | 5 | 2009 | 1241 | 0.28 | Why? |
| Coronavirus Infections | 47 | 2020 | 253789 | 0.27 | Why? |
| Saliva | 8 | 2020 | 4679 | 0.26 | Why? |
| Spike Glycoprotein, Coronavirus | 22 | 2021 | 37182 | 0.26 | Why? |
| Influenza A Virus, H3N2 Subtype | 2 | 2018 | 572 | 0.25 | Why? |
| Influenza B virus | 3 | 2018 | 815 | 0.25 | Why? |
| Enterovirus Infections | 2 | 2018 | 404 | 0.25 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 8 | 2018 | 8843 | 0.25 | Why? |
| Animals | 51 | 2021 | 78931 | 0.24 | Why? |
| Antibody Affinity | 1 | 2007 | 1078 | 0.24 | Why? |
| Influenza A Virus, H7N9 Subtype | 2 | 2019 | 415 | 0.23 | Why? |
| Mesocricetus | 3 | 2021 | 1847 | 0.22 | Why? |
| RNA, Viral | 24 | 2021 | 32276 | 0.21 | Why? |
| Vasopressins | 1 | 2021 | 70 | 0.21 | Why? |
| Adenoviridae Infections | 2 | 2018 | 150 | 0.21 | Why? |
| Enzyme-Linked Immunosorbent Assay | 14 | 2019 | 7868 | 0.21 | Why? |
| Serologic Tests | 7 | 2020 | 4359 | 0.21 | Why? |
| Aborted Fetus | 1 | 2019 | 34 | 0.21 | Why? |
| Sensitivity and Specificity | 28 | 2020 | 22971 | 0.20 | Why? |
| Viral Tropism | 4 | 2020 | 1329 | 0.20 | Why? |
| Zika Virus Infection | 3 | 2018 | 1920 | 0.20 | Why? |
| Tryptophan-tRNA Ligase | 1 | 2018 | 7 | 0.20 | Why? |
| Pneumonia, Viral | 28 | 2020 | 243684 | 0.19 | Why? |
| Rhinovirus | 3 | 2018 | 979 | 0.19 | Why? |
| Viral Proteins | 13 | 2020 | 7370 | 0.19 | Why? |
| Sequence Deletion | 2 | 2020 | 674 | 0.19 | Why? |
| Flufenamic Acid | 1 | 2018 | 6 | 0.19 | Why? |
| Coronaviridae Infections | 2 | 2014 | 442 | 0.19 | Why? |
| Defective Viruses | 1 | 2019 | 98 | 0.19 | Why? |
| Newcastle disease virus | 1 | 2019 | 108 | 0.19 | Why? |
| Bird Diseases | 2 | 2012 | 130 | 0.19 | Why? |
| Virus Replication | 13 | 2021 | 14331 | 0.19 | Why? |
| Nasopharynx | 19 | 2020 | 10224 | 0.19 | Why? |
| Zanamivir | 1 | 2018 | 63 | 0.18 | Why? |
| Caspases, Initiator | 1 | 2017 | 29 | 0.18 | Why? |
| Betacoronavirus | 18 | 2020 | 204454 | 0.18 | Why? |
| Herpes Zoster Vaccine | 1 | 2019 | 112 | 0.18 | Why? |
| Molecular Epidemiology | 8 | 2016 | 1638 | 0.17 | Why? |
| Antibodies, Neutralizing | 12 | 2021 | 25288 | 0.17 | Why? |
| Biological Assay | 1 | 2020 | 367 | 0.17 | Why? |
| Interferon beta-1b | 1 | 2020 | 274 | 0.17 | Why? |
| Clinical Laboratory Techniques | 7 | 2020 | 23402 | 0.17 | Why? |
| Humans | 135 | 2021 | 930598 | 0.17 | Why? |
| Clarithromycin | 1 | 2018 | 112 | 0.17 | Why? |
| Bromocriptine | 1 | 2017 | 42 | 0.17 | Why? |
| Caspase 1 | 1 | 2017 | 149 | 0.17 | Why? |
| Herpesvirus 3, Human | 1 | 2019 | 228 | 0.17 | Why? |
| Jugular Veins | 1 | 2017 | 52 | 0.17 | Why? |
| Mice, Inbred BALB C | 9 | 2021 | 5814 | 0.17 | Why? |
| Genetic Variation | 3 | 2020 | 3919 | 0.17 | Why? |
| Absorption, Radiation | 1 | 2016 | 16 | 0.16 | Why? |
| Evolution, Molecular | 8 | 2016 | 3691 | 0.16 | Why? |
| Electromagnetic Phenomena | 1 | 2016 | 21 | 0.16 | Why? |
| Macrophages | 3 | 2017 | 2784 | 0.16 | Why? |
| Smad7 Protein | 1 | 2016 | 32 | 0.16 | Why? |
| Virus Diseases | 3 | 2019 | 3779 | 0.16 | Why? |
| Enterovirus D, Human | 1 | 2017 | 96 | 0.16 | Why? |
| Eyelids | 1 | 2016 | 40 | 0.16 | Why? |
| Enterovirus A, Human | 1 | 2018 | 180 | 0.16 | Why? |
| Fibroblast Growth Factor 2 | 1 | 2016 | 77 | 0.16 | Why? |
| Ribavirin | 3 | 2020 | 1182 | 0.15 | Why? |
| Bronchoscopes | 1 | 2017 | 168 | 0.15 | Why? |
| Male | 70 | 2021 | 367725 | 0.15 | Why? |
| Influenza A virus | 5 | 2018 | 2234 | 0.15 | Why? |
| Cells, Cultured | 8 | 2020 | 5835 | 0.15 | Why? |
| 5' Untranslated Regions | 2 | 2017 | 375 | 0.15 | Why? |
| Cricetinae | 6 | 2021 | 3344 | 0.15 | Why? |
| Female | 68 | 2021 | 380317 | 0.15 | Why? |
| Oligonucleotide Probes | 1 | 2015 | 88 | 0.15 | Why? |
| Virus Shedding | 4 | 2020 | 5834 | 0.15 | Why? |
| Induced Pluripotent Stem Cells | 1 | 2020 | 584 | 0.15 | Why? |
| Central Venous Catheters | 1 | 2017 | 188 | 0.15 | Why? |
| Patients' Rooms | 1 | 2020 | 675 | 0.15 | Why? |
| Whole Genome Sequencing | 3 | 2021 | 3239 | 0.14 | Why? |
| Cell Line | 11 | 2021 | 12040 | 0.14 | Why? |
| Models, Anatomic | 1 | 2016 | 191 | 0.14 | Why? |
| Base Sequence | 10 | 2020 | 3581 | 0.14 | Why? |
| Thoracic Surgical Procedures | 2 | 2017 | 504 | 0.14 | Why? |
| Oligonucleotides | 1 | 2015 | 137 | 0.14 | Why? |
| Heart Valves | 1 | 2014 | 52 | 0.14 | Why? |
| Disease Models, Animal | 7 | 2020 | 10998 | 0.14 | Why? |
| Conjunctiva | 1 | 2020 | 620 | 0.14 | Why? |
| Specimen Handling | 4 | 2021 | 6190 | 0.14 | Why? |
| Rodent Diseases | 1 | 2014 | 115 | 0.13 | Why? |
| Adult | 49 | 2021 | 244371 | 0.13 | Why? |
| Myocytes, Cardiac | 1 | 2020 | 804 | 0.13 | Why? |
| Vaccines, Attenuated | 1 | 2019 | 952 | 0.13 | Why? |
| Intestines | 1 | 2020 | 817 | 0.13 | Why? |
| Fomites | 1 | 2020 | 709 | 0.13 | Why? |
| Organoids | 1 | 2020 | 840 | 0.13 | Why? |
| Middle Aged | 47 | 2021 | 270681 | 0.13 | Why? |
| Vero Cells | 10 | 2021 | 14117 | 0.13 | Why? |
| Cell Membrane | 1 | 2018 | 743 | 0.13 | Why? |
| Aged | 42 | 2021 | 215776 | 0.13 | Why? |
| Phosphoproteins | 5 | 2020 | 4346 | 0.12 | Why? |
| Serine Proteinase Inhibitors | 1 | 2017 | 341 | 0.12 | Why? |
| Viral Nonstructural Proteins | 3 | 2020 | 4810 | 0.12 | Why? |
| Transcription, Genetic | 3 | 2009 | 1326 | 0.12 | Why? |
| Common Cold | 2 | 2011 | 645 | 0.12 | Why? |
| Open Reading Frames | 5 | 2020 | 1898 | 0.12 | Why? |
| Rabbits | 2 | 2014 | 1171 | 0.12 | Why? |
| Orthomyxoviridae | 2 | 2020 | 1168 | 0.12 | Why? |
| Virus Internalization | 3 | 2021 | 7921 | 0.12 | Why? |
| Parvoviridae Infections | 2 | 2018 | 222 | 0.11 | Why? |
| Amino Acid Sequence | 10 | 2020 | 6049 | 0.11 | Why? |
| High-Throughput Nucleotide Sequencing | 2 | 2020 | 3633 | 0.11 | Why? |
| Metapneumovirus | 2 | 2018 | 465 | 0.11 | Why? |
| Genetic Vectors | 1 | 2018 | 1600 | 0.11 | Why? |
| Paramyxoviridae Infections | 2 | 2018 | 364 | 0.11 | Why? |
| Weather | 1 | 2017 | 581 | 0.11 | Why? |
| Mice | 12 | 2020 | 21357 | 0.10 | Why? |
| Acute Lung Injury | 1 | 2019 | 904 | 0.10 | Why? |
| Recombinant Proteins | 8 | 2017 | 3786 | 0.10 | Why? |
| Air Microbiology | 1 | 2020 | 1322 | 0.10 | Why? |
| Dengue Virus | 1 | 2017 | 910 | 0.10 | Why? |
| Animals, Domestic | 1 | 2012 | 272 | 0.10 | Why? |
| Seroconversion | 1 | 2020 | 2515 | 0.10 | Why? |
| Antiviral Agents | 8 | 2018 | 41703 | 0.10 | Why? |
| Cytokines | 6 | 2021 | 15010 | 0.10 | Why? |
| Viral Fusion Proteins | 1 | 2014 | 399 | 0.10 | Why? |
| Respiratory Syncytial Viruses | 3 | 2018 | 612 | 0.10 | Why? |
| Community-Acquired Infections | 2 | 2017 | 2328 | 0.10 | Why? |
| Infant | 15 | 2020 | 30274 | 0.10 | Why? |
| Child, Preschool | 16 | 2020 | 36283 | 0.10 | Why? |
| RNA Viruses | 1 | 2017 | 824 | 0.10 | Why? |
| Mammals | 1 | 2012 | 315 | 0.10 | Why? |
| Epitopes | 2 | 2020 | 4113 | 0.10 | Why? |
| Health Care Costs | 1 | 2018 | 1007 | 0.10 | Why? |
| Bronchoscopy | 1 | 2017 | 991 | 0.10 | Why? |
| Ritonavir | 2 | 2020 | 4212 | 0.09 | Why? |
| Pyrimidines | 1 | 2017 | 1557 | 0.09 | Why? |
| Endocarditis | 1 | 2014 | 368 | 0.09 | Why? |
| Epitopes, T-Lymphocyte | 1 | 2020 | 2262 | 0.09 | Why? |
| Escherichia coli Proteins | 2 | 2006 | 168 | 0.09 | Why? |
| Immunoglobulin G | 11 | 2020 | 21571 | 0.09 | Why? |
| Mutation | 4 | 2021 | 12376 | 0.09 | Why? |
| Travel-Related Illness | 1 | 2016 | 1357 | 0.09 | Why? |
| Infectious Mononucleosis | 1 | 2008 | 35 | 0.09 | Why? |
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 1645 | 0.09 | Why? |
| Lupus Erythematosus, Systemic | 1 | 2019 | 1380 | 0.09 | Why? |
| Vaccines, DNA | 2 | 2005 | 871 | 0.09 | Why? |
| Fluorescent Antibody Technique | 3 | 2005 | 835 | 0.09 | Why? |
| Polymerase Chain Reaction | 6 | 2020 | 6740 | 0.09 | Why? |
| Bocavirus | 1 | 2007 | 74 | 0.09 | Why? |
| Adolescent | 22 | 2020 | 86841 | 0.09 | Why? |
| Masks | 2 | 2020 | 8528 | 0.09 | Why? |
| Lopinavir | 3 | 2020 | 4308 | 0.09 | Why? |
| China | 10 | 2020 | 50654 | 0.09 | Why? |
| Cluster Analysis | 5 | 2016 | 3001 | 0.08 | Why? |
| Pyrimidinones | 2 | 2004 | 76 | 0.08 | Why? |
| Crossing Over, Genetic | 1 | 2006 | 11 | 0.08 | Why? |
| Viruses | 2 | 2019 | 2238 | 0.08 | Why? |
| Antigens, Viral | 5 | 2015 | 6298 | 0.08 | Why? |
| Apoptosis | 2 | 2016 | 2335 | 0.08 | Why? |
| Interferons | 2 | 2017 | 2885 | 0.08 | Why? |
| Point-of-Care Systems | 1 | 2020 | 2955 | 0.08 | Why? |
| Rats | 1 | 2014 | 2764 | 0.08 | Why? |
| Luminescence | 1 | 2007 | 236 | 0.08 | Why? |
| Disease Outbreaks | 10 | 2021 | 27595 | 0.08 | Why? |
| Immunocompetence | 1 | 2008 | 280 | 0.08 | Why? |
| Young Adult | 14 | 2020 | 93724 | 0.08 | Why? |
| Genotype | 6 | 2019 | 4697 | 0.08 | Why? |
| Cytopathogenic Effect, Viral | 2 | 2020 | 635 | 0.08 | Why? |
| Neutralization Tests | 3 | 2021 | 6698 | 0.08 | Why? |
| Temperature | 1 | 2016 | 2305 | 0.08 | Why? |
| Models, Theoretical | 2 | 2017 | 6659 | 0.08 | Why? |
| Aged, 80 and over | 18 | 2020 | 88759 | 0.08 | Why? |
| Child | 18 | 2020 | 70012 | 0.07 | Why? |
| Sequence Homology, Amino Acid | 4 | 2013 | 945 | 0.07 | Why? |
| DNA, Viral | 4 | 2017 | 2521 | 0.07 | Why? |
| Antibody Specificity | 2 | 2007 | 1328 | 0.07 | Why? |
| Influenza A Virus, H1N1 Subtype | 2 | 2018 | 2984 | 0.07 | Why? |
| Multigene Family | 1 | 2006 | 377 | 0.07 | Why? |
| Dendritic Cells | 1 | 2014 | 1330 | 0.07 | Why? |
| Genomics | 1 | 2017 | 3118 | 0.07 | Why? |
| Point-of-Care Testing | 1 | 2018 | 2782 | 0.07 | Why? |
| Hospitalization | 12 | 2020 | 54280 | 0.07 | Why? |
| Dengue | 1 | 2017 | 1565 | 0.07 | Why? |
| Disease Reservoirs | 2 | 2015 | 1672 | 0.07 | Why? |
| Influenza Vaccines | 2 | 2018 | 2941 | 0.07 | Why? |
| Interferon-alpha | 3 | 2017 | 1442 | 0.07 | Why? |
| Reproducibility of Results | 6 | 2020 | 11304 | 0.07 | Why? |
| Mannose-Binding Lectin | 1 | 2005 | 131 | 0.07 | Why? |
| Myocarditis | 1 | 2020 | 2731 | 0.07 | Why? |
| Sequence Alignment | 4 | 2014 | 2109 | 0.07 | Why? |
| Immunoassay | 1 | 2020 | 4485 | 0.07 | Why? |
| Health Resources | 1 | 2018 | 2592 | 0.07 | Why? |
| Chromatography | 1 | 2004 | 112 | 0.07 | Why? |
| Seroepidemiologic Studies | 5 | 2013 | 10017 | 0.07 | Why? |
| Reference Standards | 3 | 2020 | 1163 | 0.06 | Why? |
| Gene Expression Regulation | 2 | 2013 | 4020 | 0.06 | Why? |
| Viral Vaccines | 3 | 2020 | 7560 | 0.06 | Why? |
| Lung | 10 | 2020 | 31049 | 0.06 | Why? |
| Sequence Homology | 2 | 2016 | 448 | 0.06 | Why? |
| United Arab Emirates | 2 | 2016 | 704 | 0.06 | Why? |
| Lectins, C-Type | 1 | 2005 | 405 | 0.06 | Why? |
| Cell Adhesion Molecules | 1 | 2005 | 472 | 0.06 | Why? |
| Interleukin-1beta | 2 | 2018 | 992 | 0.06 | Why? |
| Gastroenteritis | 1 | 2007 | 489 | 0.06 | Why? |
| Picornaviridae Infections | 1 | 2007 | 544 | 0.06 | Why? |
| Immunoglobulin A | 4 | 2007 | 3567 | 0.06 | Why? |
| Venous Thrombosis | 1 | 2017 | 2739 | 0.06 | Why? |
| Nasopharyngeal Neoplasms | 1 | 2002 | 64 | 0.06 | Why? |
| Cell Survival | 2 | 2020 | 1581 | 0.06 | Why? |
| Intubation, Intratracheal | 1 | 2017 | 3962 | 0.06 | Why? |
| Kidney | 1 | 2016 | 3648 | 0.06 | Why? |
| Receptors, Cell Surface | 1 | 2005 | 586 | 0.06 | Why? |
| Communicable Diseases, Emerging | 2 | 2013 | 2523 | 0.06 | Why? |
| Protein Binding | 5 | 2021 | 11430 | 0.05 | Why? |
| Reagent Kits, Diagnostic | 2 | 2017 | 2149 | 0.05 | Why? |
| Protease Inhibitors | 1 | 2017 | 3630 | 0.05 | Why? |
| Plasmids | 1 | 2004 | 840 | 0.05 | Why? |
| Orthomyxoviridae Infections | 2 | 2019 | 1001 | 0.05 | Why? |
| Cell Line, Tumor | 3 | 2021 | 3608 | 0.05 | Why? |
| Genes, Viral | 1 | 2006 | 1428 | 0.05 | Why? |
| Inflammatory Bowel Diseases | 1 | 2018 | 3209 | 0.05 | Why? |
| HIV Protease Inhibitors | 1 | 2004 | 434 | 0.05 | Why? |
| Columbidae | 1 | 2019 | 17 | 0.05 | Why? |
| Immunoglobulin M | 4 | 2021 | 9091 | 0.05 | Why? |
| Pandemics | 21 | 2020 | 389249 | 0.05 | Why? |
| Multiplex Polymerase Chain Reaction | 2 | 2019 | 1439 | 0.05 | Why? |
| Asymptomatic Infections | 1 | 2019 | 7218 | 0.05 | Why? |
| Seasons | 4 | 2018 | 4071 | 0.05 | Why? |
| Newcastle Disease | 1 | 2019 | 46 | 0.05 | Why? |
| Respiratory Syncytial Virus Infections | 1 | 2009 | 1234 | 0.05 | Why? |
| Influenza A Virus, H9N2 Subtype | 1 | 1999 | 61 | 0.05 | Why? |
| Bronchi | 2 | 2019 | 1048 | 0.05 | Why? |
| Nucleocapsid | 1 | 2004 | 734 | 0.05 | Why? |
| Polyethylene Glycols | 1 | 2004 | 574 | 0.05 | Why? |
| False Positive Reactions | 2 | 2020 | 1338 | 0.05 | Why? |
| Animal Structures | 1 | 2018 | 61 | 0.05 | Why? |
| Time Factors | 9 | 2020 | 31397 | 0.05 | Why? |
| Microspheres | 1 | 2020 | 261 | 0.05 | Why? |
| Immunity, Innate | 2 | 2014 | 6570 | 0.05 | Why? |
| Pulmonary Alveoli | 1 | 2004 | 867 | 0.05 | Why? |
| Carcinoma | 1 | 2002 | 256 | 0.05 | Why? |
| Herpesvirus 4, Human | 1 | 2002 | 387 | 0.05 | Why? |
| Novobiocin | 1 | 2017 | 8 | 0.05 | Why? |
| Species Specificity | 3 | 2006 | 1356 | 0.04 | Why? |
| Human bocavirus | 1 | 2018 | 142 | 0.04 | Why? |
| Blotting, Western | 3 | 2005 | 863 | 0.04 | Why? |
| Fluorescent Antibody Technique, Direct | 1 | 2017 | 69 | 0.04 | Why? |
| Viral Plaque Assay | 2 | 2013 | 381 | 0.04 | Why? |
| Enterocytes | 1 | 2020 | 245 | 0.04 | Why? |
| Transduction, Genetic | 1 | 2018 | 273 | 0.04 | Why? |
| Mesalamine | 1 | 2018 | 89 | 0.04 | Why? |
| Fiber Optic Technology | 1 | 2017 | 71 | 0.04 | Why? |
| Epstein-Barr Virus Infections | 1 | 2002 | 366 | 0.04 | Why? |
| Drug Therapy, Combination | 3 | 2020 | 7268 | 0.04 | Why? |
| Birds | 2 | 2012 | 412 | 0.04 | Why? |
| Drug Evaluation, Preclinical | 2 | 2020 | 3347 | 0.04 | Why? |
| Injections, Subcutaneous | 1 | 2019 | 647 | 0.04 | Why? |
| Population Surveillance | 2 | 2017 | 4967 | 0.04 | Why? |
| Blood | 1 | 2018 | 274 | 0.04 | Why? |
| Disease Transmission, Infectious | 2 | 2012 | 9044 | 0.04 | Why? |
| One-Lung Ventilation | 1 | 2017 | 53 | 0.04 | Why? |
| Vaccination | 2 | 2019 | 19050 | 0.04 | Why? |
| Tandem Repeat Sequences | 2 | 2006 | 78 | 0.04 | Why? |
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2017 | 106 | 0.04 | Why? |
| Vaccinia virus | 1 | 2019 | 346 | 0.04 | Why? |
| In Vitro Techniques | 1 | 2020 | 1027 | 0.04 | Why? |
| Exhalation | 1 | 2020 | 441 | 0.04 | Why? |
| Auscultation | 1 | 2017 | 115 | 0.04 | Why? |
| Microarray Analysis | 2 | 2009 | 262 | 0.04 | Why? |
| Organ Culture Techniques | 1 | 2016 | 119 | 0.04 | Why? |
| Primary Cell Culture | 1 | 2017 | 501 | 0.04 | Why? |
| Pyroptosis | 1 | 2017 | 168 | 0.04 | Why? |
| Fatal Outcome | 2 | 2017 | 3438 | 0.04 | Why? |
| Genes, pol | 2 | 2005 | 38 | 0.04 | Why? |
| Host Specificity | 1 | 2020 | 926 | 0.04 | Why? |
| Enzyme Assays | 1 | 2017 | 295 | 0.04 | Why? |
| Primates | 1 | 2018 | 584 | 0.04 | Why? |
| Prospective Studies | 6 | 2019 | 43301 | 0.04 | Why? |
| Operative Time | 1 | 2017 | 450 | 0.04 | Why? |
| Serine Proteases | 1 | 2017 | 211 | 0.04 | Why? |
| Microbial Sensitivity Tests | 1 | 2004 | 2886 | 0.04 | Why? |
| Virus Cultivation | 2 | 2013 | 579 | 0.04 | Why? |
| Histocytochemistry | 1 | 2014 | 88 | 0.04 | Why? |
| British Columbia | 1 | 2017 | 512 | 0.04 | Why? |
| Macrophages, Alveolar | 1 | 2019 | 668 | 0.04 | Why? |
| Egypt | 1 | 2019 | 1211 | 0.04 | Why? |
| Fluorescence | 1 | 2017 | 475 | 0.04 | Why? |
| B7-2 Antigen | 1 | 2014 | 56 | 0.03 | Why? |
| Feces | 5 | 2007 | 4235 | 0.03 | Why? |
| Callithrix | 1 | 2016 | 288 | 0.03 | Why? |
| Family Health | 1 | 2020 | 731 | 0.03 | Why? |
| Infection Control | 2 | 2020 | 23131 | 0.03 | Why? |
| Capsid Proteins | 1 | 2017 | 365 | 0.03 | Why? |
| Confidence Intervals | 2 | 2008 | 744 | 0.03 | Why? |
| Epithelial Cells | 2 | 2019 | 3508 | 0.03 | Why? |
| Cell Differentiation | 1 | 2020 | 1338 | 0.03 | Why? |
| Vaccines, Inactivated | 1 | 2021 | 1562 | 0.03 | Why? |
| Immunization, Passive | 2 | 2021 | 10067 | 0.03 | Why? |
| Aerosols | 2 | 2020 | 5393 | 0.03 | Why? |
| Genetic Predisposition to Disease | 2 | 2005 | 4027 | 0.03 | Why? |
| Costs and Cost Analysis | 1 | 2018 | 694 | 0.03 | Why? |
| Interferon-gamma | 2 | 2018 | 2711 | 0.03 | Why? |
| Molecular Docking Simulation | 2 | 2020 | 6902 | 0.03 | Why? |
| Immunologic Tests | 1 | 2016 | 445 | 0.03 | Why? |
| Mannitol | 1 | 1992 | 34 | 0.03 | Why? |
| Laboratories, Hospital | 1 | 2017 | 489 | 0.03 | Why? |
| Anesthesia, General | 1 | 2017 | 470 | 0.03 | Why? |
| Probability | 2 | 2008 | 923 | 0.03 | Why? |
| Laryngoscopy | 1 | 2017 | 413 | 0.03 | Why? |
| Protein Subunits | 2 | 2006 | 755 | 0.03 | Why? |
| Drug Carriers | 1 | 2018 | 590 | 0.03 | Why? |
| Adenoviridae | 1 | 2018 | 1151 | 0.03 | Why? |
| Asymptomatic Diseases | 2 | 2017 | 3444 | 0.03 | Why? |
| Intestinal Mucosa | 1 | 2020 | 1046 | 0.03 | Why? |
| Oropharynx | 1 | 2020 | 1581 | 0.03 | Why? |
| Peptides | 3 | 2014 | 2513 | 0.03 | Why? |
| Limit of Detection | 1 | 2020 | 2698 | 0.03 | Why? |
| Ships | 1 | 2020 | 1046 | 0.03 | Why? |
| Conserved Sequence | 2 | 2005 | 751 | 0.03 | Why? |
| Follow-Up Studies | 3 | 2019 | 17020 | 0.03 | Why? |
| Diarrhea | 1 | 2004 | 2743 | 0.03 | Why? |
| Infant, Newborn | 3 | 2018 | 23105 | 0.03 | Why? |
| Dipeptidyl Peptidase 4 | 1 | 2018 | 1061 | 0.03 | Why? |
| Mycophenolic Acid | 1 | 2013 | 383 | 0.03 | Why? |
| Adaptation, Biological | 1 | 2012 | 179 | 0.03 | Why? |
| Respiratory Mucosa | 1 | 2020 | 1522 | 0.03 | Why? |
| Sequence Analysis, RNA | 1 | 2020 | 2290 | 0.03 | Why? |
| Drug Discovery | 2 | 2017 | 3092 | 0.03 | Why? |
| Virus Attachment | 1 | 2018 | 1259 | 0.03 | Why? |
| Haplorhini | 1 | 2012 | 307 | 0.03 | Why? |
| Histocompatibility Antigens Class II | 1 | 2014 | 383 | 0.03 | Why? |
| Microscopy | 1 | 2014 | 414 | 0.03 | Why? |
| Multivariate Analysis | 2 | 2017 | 5440 | 0.03 | Why? |
| Inflammasomes | 1 | 2017 | 710 | 0.03 | Why? |
| Inflammation | 1 | 2013 | 13255 | 0.03 | Why? |
| Cohort Studies | 5 | 2018 | 36005 | 0.03 | Why? |
| United States Food and Drug Administration | 1 | 2018 | 1276 | 0.03 | Why? |
| Morbidity | 1 | 2017 | 1426 | 0.03 | Why? |
| Autopsy | 2 | 2014 | 3495 | 0.03 | Why? |
| Vaccines, Synthetic | 2 | 2018 | 3231 | 0.03 | Why? |
| Radiography, Thoracic | 2 | 2020 | 5486 | 0.03 | Why? |
| Thorax | 1 | 2020 | 1873 | 0.03 | Why? |
| DNA-Directed RNA Polymerases | 1 | 2011 | 239 | 0.03 | Why? |
| Antigen Presentation | 1 | 2013 | 524 | 0.03 | Why? |
| Cattle | 1 | 2014 | 1336 | 0.03 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.03 | Why? |
| Rodentia | 1 | 2012 | 235 | 0.03 | Why? |
| Demography | 1 | 2017 | 1660 | 0.02 | Why? |
| Immunity, Cellular | 2 | 2018 | 3614 | 0.02 | Why? |
| Synteny | 1 | 2008 | 38 | 0.02 | Why? |
| Fibroblasts | 1 | 2013 | 839 | 0.02 | Why? |
| Peptide Hydrolases | 1 | 2017 | 1269 | 0.02 | Why? |
| Small Molecule Libraries | 1 | 2017 | 1060 | 0.02 | Why? |
| Macaca mulatta | 1 | 2019 | 3716 | 0.02 | Why? |
| Drug Approval | 1 | 2018 | 1325 | 0.02 | Why? |
| Survival Analysis | 2 | 2017 | 7592 | 0.02 | Why? |
| Middle East | 1 | 2013 | 1418 | 0.02 | Why? |
| beta-Endorphin | 1 | 1987 | 3 | 0.02 | Why? |
| Host-Pathogen Interactions | 2 | 2021 | 11041 | 0.02 | Why? |
| Pharynx | 2 | 2007 | 1544 | 0.02 | Why? |
| Healthy Volunteers | 1 | 2014 | 1444 | 0.02 | Why? |
| Models, Molecular | 2 | 2017 | 7616 | 0.02 | Why? |
| Biopsy | 1 | 2017 | 2811 | 0.02 | Why? |
| Genome | 1 | 2010 | 341 | 0.02 | Why? |
| Respiratory System | 1 | 2020 | 3213 | 0.02 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2018 | 2483 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| Narcotics | 1 | 1987 | 67 | 0.02 | Why? |
| Administration, Oral | 2 | 2005 | 2340 | 0.02 | Why? |
| Hydrogen Peroxide | 1 | 1992 | 680 | 0.02 | Why? |
| Risk Factors | 6 | 2017 | 71621 | 0.02 | Why? |
| Japan | 1 | 2020 | 6653 | 0.02 | Why? |
| Age Distribution | 2 | 2008 | 3567 | 0.02 | Why? |
| Enzyme Inhibitors | 1 | 2017 | 1881 | 0.02 | Why? |
| Injections, Intraperitoneal | 1 | 2005 | 69 | 0.02 | Why? |
| Protein Conformation | 1 | 2017 | 4386 | 0.02 | Why? |
| Cost of Illness | 1 | 2017 | 1903 | 0.02 | Why? |
| Retrospective Studies | 5 | 2020 | 105322 | 0.02 | Why? |
| Crystallography, X-Ray | 1 | 2014 | 2689 | 0.02 | Why? |
| Body Weight | 1 | 2012 | 1074 | 0.02 | Why? |
| Seizures, Febrile | 1 | 2006 | 59 | 0.02 | Why? |
| Genes | 1 | 2005 | 50 | 0.02 | Why? |
| Coronary Artery Bypass | 1 | 1992 | 629 | 0.02 | Why? |
| Radiography | 2 | 2004 | 1576 | 0.02 | Why? |
| Chemokines, CXC | 1 | 2005 | 68 | 0.02 | Why? |
| Rimantadine | 1 | 2004 | 13 | 0.02 | Why? |
| Chlorogenic Acid | 1 | 2004 | 25 | 0.02 | Why? |
| Reference Values | 1 | 2008 | 795 | 0.02 | Why? |
| Antibodies, Monoclonal | 3 | 2015 | 8041 | 0.02 | Why? |
| Nucleic Acid Amplification Techniques | 3 | 2004 | 3388 | 0.02 | Why? |
| Combinatorial Chemistry Techniques | 1 | 2004 | 54 | 0.02 | Why? |
| Severity of Illness Index | 5 | 2020 | 48226 | 0.02 | Why? |
| Cats | 1 | 2012 | 1890 | 0.02 | Why? |
| Homozygote | 1 | 2005 | 230 | 0.02 | Why? |
| RNA, Ribosomal, 18S | 1 | 2004 | 68 | 0.02 | Why? |
| DNA, Ribosomal | 1 | 2004 | 112 | 0.02 | Why? |
| Carboxypeptidases | 1 | 2004 | 148 | 0.02 | Why? |
| Bacterial Vaccines | 1 | 2005 | 139 | 0.02 | Why? |
| Proteasome Endopeptidase Complex | 1 | 2005 | 249 | 0.02 | Why? |
| High-Throughput Screening Assays | 1 | 2013 | 1783 | 0.02 | Why? |
| Treatment Outcome | 3 | 2019 | 51732 | 0.02 | Why? |
| Dogs | 1 | 2012 | 2529 | 0.02 | Why? |
| Epidemiological Monitoring | 1 | 2017 | 3493 | 0.02 | Why? |
| Pneumonia | 1 | 2004 | 5652 | 0.02 | Why? |
| Codon | 1 | 2005 | 287 | 0.02 | Why? |
| Endemic Diseases | 1 | 2008 | 480 | 0.02 | Why? |
| Ofloxacin | 1 | 2003 | 23 | 0.02 | Why? |
| Interleukin-4 | 1 | 2005 | 367 | 0.02 | Why? |
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 343 | 0.02 | Why? |
| Acute Disease | 2 | 2007 | 6029 | 0.02 | Why? |
| Amoxicillin-Potassium Clavulanate Combination | 1 | 2003 | 72 | 0.02 | Why? |
| T-Lymphocytes | 1 | 2021 | 6670 | 0.02 | Why? |
| Immunity, Humoral | 1 | 2018 | 4849 | 0.02 | Why? |
| CHO Cells | 1 | 2005 | 831 | 0.02 | Why? |
| Pulse Therapy, Drug | 1 | 2003 | 137 | 0.02 | Why? |
| Pain, Postoperative | 1 | 1987 | 289 | 0.02 | Why? |
| Nucleic Acid Conformation | 1 | 2006 | 621 | 0.02 | Why? |
| Peptidyl-Dipeptidase A | 2 | 2020 | 9659 | 0.02 | Why? |
| Cricetulus | 1 | 2005 | 936 | 0.02 | Why? |
| Polymorphism, Genetic | 1 | 2010 | 1074 | 0.02 | Why? |
| Epstein-Barr Virus Nuclear Antigens | 1 | 2002 | 7 | 0.02 | Why? |
| Chemokine CCL2 | 1 | 2005 | 389 | 0.02 | Why? |
| Injections, Intramuscular | 1 | 2005 | 800 | 0.02 | Why? |
| Comorbidity | 3 | 2017 | 34796 | 0.02 | Why? |
| Swine | 1 | 2012 | 3352 | 0.02 | Why? |
| Intestine, Small | 1 | 2005 | 336 | 0.02 | Why? |
| Antibodies, Bacterial | 1 | 2006 | 510 | 0.02 | Why? |
| Liver | 1 | 2017 | 4007 | 0.01 | Why? |
| Models, Animal | 1 | 2005 | 788 | 0.01 | Why? |
| Glycyrrhizic Acid | 1 | 2004 | 190 | 0.01 | Why? |
| Computer Simulation | 1 | 2017 | 4982 | 0.01 | Why? |
| 3' Untranslated Regions | 1 | 2003 | 318 | 0.01 | Why? |
| Prognosis | 4 | 2008 | 32490 | 0.01 | Why? |
| Immunocompromised Host | 1 | 2018 | 5150 | 0.01 | Why? |
| Interferon beta-1a | 1 | 2004 | 316 | 0.01 | Why? |
| Survival Rate | 2 | 2008 | 9206 | 0.01 | Why? |
| DNA, Complementary | 1 | 2003 | 568 | 0.01 | Why? |
| Drug Synergism | 1 | 2004 | 833 | 0.01 | Why? |
| Databases, Nucleic Acid | 1 | 2004 | 272 | 0.01 | Why? |
| Ultrasonography | 1 | 2017 | 4409 | 0.01 | Why? |
| Odds Ratio | 2 | 2004 | 5861 | 0.01 | Why? |
| Chemokine CXCL10 | 1 | 2005 | 565 | 0.01 | Why? |
| Sex Distribution | 1 | 2008 | 2083 | 0.01 | Why? |
| Zoonoses | 1 | 2015 | 3034 | 0.01 | Why? |
| Analysis of Variance | 1 | 2004 | 950 | 0.01 | Why? |
| Trans-Activators | 1 | 2002 | 170 | 0.01 | Why? |
| Microscopy, Electron | 1 | 2003 | 830 | 0.01 | Why? |
| Disease Progression | 3 | 2004 | 13580 | 0.01 | Why? |
| Contact Tracing | 1 | 2020 | 8448 | 0.01 | Why? |
| Incidence | 3 | 2009 | 25622 | 0.01 | Why? |
| Flavonoids | 1 | 2004 | 492 | 0.01 | Why? |
| Hemagglutination Inhibition Tests | 1 | 1999 | 191 | 0.01 | Why? |
| Macaca fascicularis | 1 | 2004 | 1009 | 0.01 | Why? |
| Molecular Structure | 1 | 2004 | 1539 | 0.01 | Why? |
| Coinfection | 1 | 2019 | 6820 | 0.01 | Why? |
| Virology | 1 | 2003 | 489 | 0.01 | Why? |
| Infusions, Intravenous | 1 | 2003 | 1224 | 0.01 | Why? |
| DNA-Binding Proteins | 1 | 2002 | 469 | 0.01 | Why? |
| Vietnam | 1 | 2004 | 1665 | 0.01 | Why? |
| Complement Activation | 1 | 2005 | 949 | 0.01 | Why? |
| Immunization Schedule | 1 | 2005 | 1305 | 0.01 | Why? |
| Interferon-beta | 1 | 2004 | 979 | 0.01 | Why? |
| Nasal Cavity | 1 | 2004 | 909 | 0.01 | Why? |
| Steroids | 1 | 2004 | 904 | 0.01 | Why? |
| Immunization, Secondary | 1 | 2005 | 1649 | 0.01 | Why? |
| Antibodies | 1 | 2004 | 846 | 0.01 | Why? |
| Pilot Projects | 1 | 2009 | 5182 | 0.01 | Why? |
| Opportunistic Infections | 1 | 2003 | 602 | 0.01 | Why? |
| Epidemics | 1 | 2017 | 6407 | 0.01 | Why? |
| Viral Matrix Proteins | 1 | 2004 | 1243 | 0.01 | Why? |
| Prevalence | 2 | 2008 | 25773 | 0.01 | Why? |
| Immunization | 1 | 2004 | 2019 | 0.01 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.01 | Why? |
| Singapore | 1 | 2004 | 3641 | 0.01 | Why? |
| Gene Expression Profiling | 1 | 2005 | 3788 | 0.01 | Why? |
| Gene Expression | 1 | 2004 | 3332 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.01 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.01 | Why? |
| Hospital Mortality | 1 | 2017 | 22087 | 0.01 | Why? |
| Free Radicals | 1 | 1992 | 55 | 0.01 | Why? |
| Proportional Hazards Models | 1 | 2004 | 6543 | 0.01 | Why? |
| Cross Infection | 2 | 2004 | 8675 | 0.01 | Why? |
| Risk Assessment | 2 | 2006 | 25439 | 0.01 | Why? |
| United States | 1 | 2018 | 46150 | 0.01 | Why? |
| RNA, Messenger | 1 | 2005 | 5131 | 0.01 | Why? |
| Canada | 1 | 2004 | 6018 | 0.01 | Why? |
| Antibody Formation | 1 | 2004 | 4038 | 0.01 | Why? |
| World Health Organization | 1 | 2003 | 4213 | 0.01 | Why? |
| Blood Donors | 1 | 2004 | 2956 | 0.01 | Why? |
| Risk | 1 | 2002 | 5288 | 0.01 | Why? |
| Asthma | 1 | 2007 | 4383 | 0.01 | Why? |
| Meperidine | 1 | 1987 | 4 | 0.01 | Why? |
| Injections, Epidural | 1 | 1987 | 45 | 0.01 | Why? |
| Adrenocorticotropic Hormone | 1 | 1987 | 107 | 0.01 | Why? |
| Morphine | 1 | 1987 | 71 | 0.01 | Why? |
| Laboratories | 1 | 1999 | 2858 | 0.00 | Why? |
| Length of Stay | 1 | 2003 | 11042 | 0.00 | Why? |
| Case-Control Studies | 1 | 2004 | 17671 | 0.00 | Why? |
| Age Factors | 1 | 2004 | 21039 | 0.00 | Why? |
| Pregnancy | 1 | 2003 | 23879 | 0.00 | Why? |
| Biomarkers | 1 | 2002 | 23361 | 0.00 | Why? |
| Pregnancy Complications, Infectious | 1 | 2003 | 11559 | 0.00 | Why? |